title: Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex.
abstract: The distribution of apolipoprotein E (APOE) genotypes as a function of age and sex has been examined in a French population of 417 Alzheimer disease (AD) patients and 1,030 control subjects. When compared to the APOE epsilon3 allele, an increased risk associated with the APOE epsilon4 allele (odds ratio [OR] [epsilon4] = 2.7 with 95% confidence interval [CI] = 2.0-3.6; P < .001) and a protective effect of the APOE epsilon2 allele (OR[epsilon2] = 0.5 with 95% CI = 0.3-0.98; P = .012) were retrieved. An effect of the epsilon4 allele dosage on susceptibility was confirmed (OR[epsilon4/epsilon4] vs. the epsilon3/epsilon3 genotype = 11.2 [95% CI = 4.0-31.6]; OR[epsilon3/epsilon4] vs. the epsilon3/epsilon3 genotype = 2.2 [95% CI = 1.5-3.5]). The frequency of the epsilon4 allele was lower in male cases than in female cases, but, since a similar difference was found in controls, this does not lead to a difference in OR between sex. ORs for the epsilon4 allele versus the epsilon3 allele, OR(epsilon4), were not equal in all age classes: OR(epsilon4) in the extreme groups with onset at < 60 years or > 79 years were significantly lower than those from the age groups 60-79 years. In epsilon3/epsilon4 individuals, sex-specific lifetime risk estimates by age 85 years (i.e., sex-specific penetrances by age 85 years) were 0.14 (95% CI 0.04-0.30) for men and 0.17 (95% CI 0.09-0.28) for women.
authors.affiliation: INSERM U155, Château de Longchamp, Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Bickeböller
authors.forename: D
authors.initials: D
authors.lastname: Campion
authors.forename: A
authors.initials: A
authors.lastname: Brice
authors.forename: P
authors.initials: P
authors.lastname: Amouyel
authors.forename: D
authors.initials: D
authors.lastname: Hannequin
authors.forename: O
authors.initials: O
authors.lastname: Didierjean
authors.forename: C
authors.initials: C
authors.lastname: Penet
authors.forename: C
authors.initials: C
authors.lastname: Martin
authors.forename: J
authors.initials: J
authors.lastname: Pérez-Tur
authors.forename: A
authors.initials: A
authors.lastname: Michon
authors.forename: B
authors.initials: B
authors.lastname: Dubois
authors.forename: F
authors.initials: F
authors.lastname: Ledoze
authors.forename: C
authors.initials: C
authors.lastname: Thomas-Anterion
authors.forename: F
authors.initials: F
authors.lastname: Pasquier
authors.forename: M
authors.initials: M
authors.lastname: Puel
authors.forename: J F
authors.initials: JF
authors.lastname: Demonet
authors.forename: O
authors.initials: O
authors.lastname: Moreaud
authors.forename: M C
authors.initials: MC
authors.lastname: Babron
authors.forename: D
authors.initials: D
authors.lastname: Meulien
authors.forename: D
authors.initials: D
authors.lastname: Guez
authors.forename: M C
authors.initials: MC
authors.lastname: Chartier-Harlin
authors.forename: T
authors.initials: T
authors.lastname: Frebourg
authors.forename: Y
authors.initials: Y
authors.lastname: Agid
authors.forename: M
authors.initials: M
authors.lastname: Martinez
authors.forename: F
authors.initials: F
authors.lastname: Clerget-Darpoux
mesh_terms: D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D000544:Alzheimer Disease / Q000235:genetics*; D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D012307:Risk Factors; D012727:Sex Characteristics
chemical_list: D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E